Triple attack: new cell therapy combo takes on melanoma

NCT ID NCT06739226

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial tests a combination of three immune cell therapies—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell vaccines—against advanced melanoma that has not responded to standard treatment. The study aims to see if this approach is safe and can shrink tumors in 30 adult patients. Researchers will also monitor how long the immune cells last in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Combination of CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines targeting melanoma antigens
What this could lead to: If successful, this could offer a new treatment option for advanced melanoma that has not responded to standard therapy.
What could go wrong: This is an early-phase trial with only 30 participants, so results may not apply broadly. Side effects from the cell therapies could be significant, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

Shenzhen Geno-Immune Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.